Corrigenda

Corrigendum to Arif et al. VDAC1 is a molecular target in glioblastoma, with its depletion leading to reprogrammed metabolism and reversed oncogenic properties. Neuro Oncol (doi:10.1093/neuonc/now297) first published online February 28, 2017.

The authors have corrected the spelling of an author’s name: “Yakov Kerlin” should be “Yakov Krelin”.